Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 436 in MSI-H/dMMR Solid Tumors
NCT07403721Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Apr 2026
- Primary completion
- Jan 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 10
01
Overview
Phase 1, open-label trial of AMG 436 in solid tumor (5 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity at 21 days and Treatment-emergent Adverse Events and Serious Adverse Events at 5 years. Started Apr 2026; status: recruiting.
02
Drugs
AMG 436
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07403721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403721.